Fingolimod Real World Experience: Efficacy and Safety in Clinical Practice.

Neurosci J · 2015 · PMC4674597 · PMID 26693475

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In clinical trials, the Basal Cell Carcinoma (BCC) showed a trend towards a bigger incidence with fingolimod 0.5 mg than with placebo [ 14 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.